- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05377320
Similitud del paciente para la toma de decisiones en la prevención de la toxicidad cardiovascular (PACT): un estudio de viabilidad
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
For this feasibility study, the researchers will create the clinical decision aid and test the central hypothesis that this novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists and will favorably impact appropriate medication use and cardiac imaging surveillance. The hypothesis is supported by preliminary data suggesting that an initial and rudimentary version of the clinical aid increases appropriate medication use and imaging follow-up in cardio-oncology patients. Success will be determined by ≥85% of clinic visits using the clinical decision aid resulting in pursuit of medication use and cardiac imaging surveillance patterns commensurate with recommendations specific to cancer survivors, with overall rates the same or higher than the group without the clinical decision aid, as well as overall favorable patient and physician focus group comments and survey responses.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Yee Chung Cheng, MD
- Número de teléfono: 414-805-4600
- Correo electrónico: ycheng@mcw.edu
Ubicaciones de estudio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Froedtert & the Medical College of Wisconsin
-
Investigador principal:
- Yee Chung Chen, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Cancer survivors at intermediate, high, or very high risk for developing cardiovascular disease will pursue a cardio-oncology visit.
Descripción
Inclusion Criteria:
- Patients ≥18 years with a history of cancer.
- Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
- Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
- Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Exclusion Criteria:
- Patient <18 years.
- Without a personal history of cancer.
- Existing cardiomyopathy diagnosed after cancer diagnosis.
- Documented cognitive impairment.
- Patient or patient representative who is unable and unwilling to sign the informed consent form.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Clinical Decision Aid Group
In this group, physicians will use standard care plus the clinical decision aid. |
The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24. |
|
Control Group
In this group, physicians will use standard care only. |
Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Medication use
Periodo de tiempo: Week 0
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Medication use
Periodo de tiempo: Week 12
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Medication use
Periodo de tiempo: Week 24
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
|
Imaging surveillance
Periodo de tiempo: Week 0
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Imaging surveillance
Periodo de tiempo: Week 12
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Imaging surveillance
Periodo de tiempo: Week 24
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yee Chung Cheng, MD, Medical College of Wisconsin
Publicaciones y enlaces útiles
Publicaciones Generales
- Brown SA, Chung BY, Doshi K, Hamid A, Pederson E, Maddula R, Hanna A, Choudhuri I, Sparapani R, Bagheri Mohamadi Pour M, Zhang J, Kothari AN, Collier P, Caraballo P, Noseworthy P, Arruda-Olson A; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity (CAIPE) Research Team Investigators. Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT): a feasibility trial design. Cardiooncology. 2023 Jan 23;9(1):7. doi: 10.1186/s40959-022-00151-0.
- Brown SA, Hamid A, Pederson E, Bs AH, Maddula R, Goodman R, Lamberg M, Caraballo P, Noseworthy P, Lukan O, Echefu G, Berman G, Choudhuri I; Cardio-Oncology Artificial Intelligence Informatics & Precision Equity (CAIPE) and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity (PACT) Research Team Investigators. Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology. Cardiooncology. 2023 Oct 27;9(1):37. doi: 10.1186/s40959-023-00179-w.
- Brown SA, Fang MZ, Sparapani R, Zhou Y, Osinski K, Taylor B, Yu D, Blessing J, Shah R, Collier P, BagheriMohamadiPour M, Zhang J, Kothari A, Echefu G, Rickards J, Otto C, Sanchez Z, Olson J, Arruda-Olson A, Cheng YC, Cheng F; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity, and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity Research Team Investigators. PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors. J Am Heart Assoc. 2025 Dec 16;14(24):e030363. doi: 10.1161/JAHA.123.030363. Epub 2025 Dec 11.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Heridas y Lesiones
- Procesos Patológicos
- Enfermedades cardíacas
- Enfermedades metabólicas
- Trastornos del metabolismo de la glucosa
- Trastornos inducidos químicamente
- Efectos secundarios y reacciones adversas relacionados con los medicamentos
- Lesiones por radiación
- Aterosclerosis
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Enfermedades vasculares periféricas
- Enfermedad coronaria
- Isquemia miocardica
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Neoplasias
- Insuficiencia cardiaca
- Hipertensión
- Isquemia
- Diabetes mellitus
- Miocardiopatías
- Enfermedad arterial periférica
- Enfermedad de la arteria coronaria
- Cardiotoxicidad
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Calidad de la atención médica
- Indicadores de calidad, atención médica
- Estándar de cuidado
Otros números de identificación del estudio
- PRO00039290
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .